TY - JOUR
T1 - Kawasaki disease
T2 - Guidelines of Italian Society of Pediatrics, part II - Treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks
AU - Marchesi, Alessandra
AU - Tarissi De Jacobis, Isabella
AU - Rigante, Donato
AU - Rimini, Alessandro
AU - Malorni, Walter
AU - Corsello, Giovanni
AU - Bossi, Grazia
AU - Buonuomo, Sabrina
AU - Cardinale, Fabio
AU - Cortis, Elisabetta
AU - De Benedetti, Fabrizio
AU - De Zorzi, Andrea
AU - Duse, Marzia
AU - Del Principe, Domenico
AU - Dellepiane, Rosa Maria
AU - D'Isanto, Livio
AU - El Hachem, Maya
AU - Esposito, Susanna
AU - Falcini, Fernanda
AU - Giordano, Ugo
AU - Maggio, Maria Cristina
AU - Mannarino, Savina
AU - Marseglia, Gianluigi
AU - Martino, Silvana
AU - Marucci, Giulia
AU - Massaro, Rossella
AU - Pescosolido, Christian
AU - Pietraforte, Donatella
AU - Pietrogrande, Maria Cristina
AU - Salice, Patrizia
AU - Secinaro, Aurelio
AU - Straface, Elisabetta
AU - Villani, Alberto
PY - 2018/8/30
Y1 - 2018/8/30
N2 - This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications.
AB - This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set of 17 recommendations. Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and practitioners, as treatment modalities other than those recommended may be required as a result of peculiar medical circumstances, patient's condition, and disease severity or individual complications.
KW - Aspirin
KW - Child
KW - Coronary artery abnormalities
KW - Innovative biotechnologies
KW - Intravenous immunoglobulin
KW - Kawasaki disease
KW - Personalized medicine
UR - http://www.scopus.com/inward/record.url?scp=85052725593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052725593&partnerID=8YFLogxK
U2 - 10.1186/s13052-018-0529-2
DO - 10.1186/s13052-018-0529-2
M3 - Review article
AN - SCOPUS:85052725593
VL - 44
JO - Italian Journal of Pediatrics
JF - Italian Journal of Pediatrics
SN - 1720-8424
IS - 1
M1 - 103
ER -